Slide 1: Q1 FY-2025 Earnings Call
Q1 FY-2025 Earnings Call May 7, 2025
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this presentation which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans, or predictions of the future, are forward-looking statements within the meaning of the
Slide 3: Cryoport – Trusted Partner to Life Sciences Companies
Cryoport – Trusted Partner to Life Sciences Companies Life sciences company focused on providing mission critical, proprietary temperature-controlled supply chain solutions Capabilities include core competencies to ship, store and deliver biologics in a cryogenic or temperature-controlled state such
Slide 4: Cryoport, Inc.
Cryoport, Inc. © 2025 CRYOPORT, INC. 4
Slide 5: Cryoport – Q1 2025 Snapshot
Cryoport – Q1 2025 Snapshot (all data from continuing operations) Performance Recent News Strategic Partnership with DHL Group and all cash divestiture of CRYOPDP $244M specialty courier ($195M $41.0M $165 - $172M FY 2025 Revenue enterprise value) expected Q1-2025 Revenue Cash & Short-Term Guidance
Slide 6: Supporting Growing Cell & Gene Therapy Clinical Trial Pipeline
Supporting Growing Cell & Gene Therapy Clinical Trial Pipeline ✓711 clinical trials (net) in aggregate Clinical Trials Supported by Trial ✓ 79 Phase III trials in the Americas, EMEA and APAC Phase as of 3/31/25 Increased by 36 trials (net) over Q1 2024 Source: Company materials cross-referenced to c
Slide 7: LS Services Key Revenue Growth Drivers
LS Services Key Revenue Growth Drivers Commercial CGT Revenue BioStorage/BioServices ($ in millions) Revenue ($ in millions) $7.2 $4.3 $5.4 $3.5 +33% YoY +23% YoY Q1 2024 Q1 2025 Q1 2024 Q1 2025 © 2025 CRYOPORT, INC. 7
Slide 8: Q1 2025 Revenue
Q1 2025 Revenue © 2025 CRYOPORT, INC. 8
Slide 9: Cryoport Supports 20 Commercial Cell & Gene Therapies
Cryoport Supports 20 Commercial Cell & Gene Therapies AKUUGO® © 2025 CRYOPORT, INC. 9
Slide 10: Balance Sheet
Balance Sheet © 2025 CRYOPORT, INC. 10
Slide 11: Statement of Operations
Statement of Operations © 2025 CRYOPORT, INC. 11
Slide 12: The Leading Cryogenic Systems Manufacturer in the World
The Leading Cryogenic Systems Manufacturer in the World MVE Biological Solutions is the leading manufacturer of cryogenic systems, providing cryogenic freezers, dewars, and related equipment used for cryogenic storage and transportation • Three primary locations o Ball Ground, GA o New Prague, MN o
Slide 13: CRYOGENE Will Be Exclusive Supplier to Speros/Moffitt Cancer Center
CRYOGENE Will Be Exclusive Supplier to Speros/Moffitt Cancer Center • 30,000 sq ft facility with exclusivity for biorepository services • Construction to begin Q2 2025 • Biological material transfers begin Q2 2026 • CRYOGENE will provide our services to biotech, research, and pharma companies in the
Slide 14: MVE Biological Solutions’ FDA Registration
MVE Biological Solutions’ FDA Registration © 2025 CRYOPORT, INC. 14
Slide 15: Cryoport Systems’ Proprietary Shipper Fleet
Cryoport Systems’ Proprietary Shipper Fleet Cryoport Express ® High Volume Dry Vapor Shipper CXHV3 CryoMax® Cryogenic -150° C or colder Lab Move Shipper C1536PD 21 days at -150°C or colder Cryoport Elite 28L Ultra Cryoport Elite 56L Ultra Cold Shipper ELUC128 Cold Shipper ELUC156 -60° C to -80° C -6
Slide 16: IntegriCell - a Unique Platform for Starting Materials
IntegriCell - a Unique Platform for Starting Materials A standardized cryopreservation and distribution solution for the global cell therapy market located in Villers le Bouillet, Belgium and Houston, Texas Apheresis Global Supply Chain Partners Centers Collection Cryopreservation Storage & Distribu
Slide 17: IntegriCell Vision
IntegriCell Vision To establish a standardized cryopreservation and distribution solution for the global cell and gene therapy market • IntegriCell combines: o Cryoport Systems’ global leadership in temperature-controlled supply chain solutions and storage o Cryopreservation experience and expertise
Slide 18: IntegriCell Current Footprint
IntegriCell Current Footprint Villers-le-Bouillet, Liège, BELGIUM Houston, USA CRYO Manufacturing CRYO Manufacturing • Cryopreservation Process Development • Cryopreservation Manufacturing for Clinical Grade/GMP • Cryopreservation Manufacturing for Clinical Grade/GMP compliant (1,000 units/year) com
Slide 19: Cryoport Systems' Platform Solution
Cryoport Systems' Platform Solution Comprehensive Supply Chain Management © 2025 CRYOPORT, INC. 19
Slide 20: Upcoming Investor Conferences
Upcoming Investor Conferences © 2025 CRYOPORT, INC. 20
Slide 21: Unparalleled Informatics Technology
Unparalleled Informatics Technology World-Class Technology & Innovation • The Cryoport Systems Shipping Solution, comprised of the Cryoportal®, Smartpak II®, and round-the-clock client support, work together to reduce/manage risk, allow for proactive monitoring, and includes intervention capabilitie
Slide 22: Cryoport’s Logistics Management Made Easy
Cryoport’s Logistics Management Made Easy It’s as simple as a couple of clicks • Log into the Cryoportal® to create an order or select a prepopulated template • Carrier options, such as our Cryoshuttle®, integrators, and couriers or any combination to meet your specific shipment need are available •